Skip to main content
SpringerLink
Log in
Book cover

Handbook of Psychocardiology pp 303–316Cite as

Psychoses and Cardiovascular Disease: The Heart and Mind of the Matter

  • Reference work entry
  • First Online:

  • 2124 Accesses

Abstract

Cardiovascular disease and its risk factors are markedly overrepresented in people suffering with psychotic disorders such as schizophrenia. Adverse sequelae of this association include heightened mortality, worsened quality of life, and course of mental illness. Of further concern are that cardiovascular disease is underreported and neglected in this population as well as low rate of metabolic screening. The relationship of cardiovascular disease to psychosis is a complex one, with core symptoms of psychosis, poor diet, smoking, sedentary lifestyle, and socioeconomic factors predisposing to cardiovascular risk. These factors act in combination with iatrogenically induced risk factors attributed to antipsychotic medication, in particular weight gain. There are also syndromes that predispose to both psychosis and cardiovascular disease, including velocardiofacial syndrome, homocystinuria, and Cushing’s syndrome and possibly pro-inflammatory mechanisms. Psychotic symptoms are also independently associated with coronary artery bypass and valve surgery. Stress plays a role in the negative impact on both psychosis and cardiovascular disease via the hypothalamic-pituitary-adrenal axis.

Regular metabolic monitoring and intervention for identified cardiovascular risk factors in psychosis are mandatory. The latter includes education about diet, exercise, and cardiac risk factors, as well as minimization of weight gain and sedation associated with antipsychotic medication, with switching to more weight-neutral and tolerable medication options. Metformin appears to have a role in ameliorating antipsychotic-related weight gain. While there is a limited evidence base about psychological and psychotherapeutic interventions for primary or secondary prevention of cardiac disease in people with psychoses, behavioral and lifestyle interventions have emerged as showing benefit. Varenicline, a medication not without its propsychotic risks, may also complement these lifestyle interventions via facilitation of smoking cessation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   599.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   799.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Association.

    Google Scholar 

  • Andreassen, O. A., Djurovic, S., Thompson, W. K., Schork, A. J., Kendler, K. S., O’Donovan, M. C., Rujescu, D.,… McCarthy, M. I. International Consortium for Blood Pressure GWAS; Diabetes Genetics Replication and Meta-analysis Consortium; Psychiatric Genomics Consortium Schizophrenia Working Group. Roddey, J. C., McEvoy, L. K., Desikan, R. S., Dale, A. M. (2013). Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. American Journal of Human Genetics, 92(2), 197–209.

    Google Scholar 

  • Baker, A., Richmond, R., Castle, D., Kulkarni, J., Kay-Lambkin, F., Sakrouge, R., Filia, S., & Lewin, T. J. (2009). Coronary heart disease reduction intervention among overweight smokers with a psychotic disorder: Pilot trial. Australian and New Zealand Journal of Psychiatry, 43, 129–135.

    Article  PubMed  Google Scholar 

  • Baker, A., Frances, J., Kay-Lambkin, F. J., Richmond, R., Filia, S., Castle, D., Williams, J., & Lewin, T. J. (2011). Study protocol: A randomised controlled trial investigating the effect of a healthy lifestyle intervention for people with severe mental disorders. BMC Public Health, 11, 10. doi:10.1186/1471-2458-11-10.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bancila, V., Dallon, C., & Zullino, D. F. (2009). Varenicline may induce psychotic symptoms in subjects without previous history of psychiatric disorders. Acta Neuropsychiatrica, 21(5), 268–269.

    Article  Google Scholar 

  • Baptista, T. (1999). Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatrica Scandanavica, 100, 3–16.

    Article  Google Scholar 

  • Beratis, S., Katrivanou, A., & Gourzis, P. (2001). Factors affecting smoking in schizophrenia. Comprehensive Psychiatry, 42(5), 393–402.

    Article  PubMed  Google Scholar 

  • Bosanac, P., & Castle, D. (2012). Schizophrenia and depression. Medical Journal of Australia, 1(supplement 4), 36–39.

    Article  Google Scholar 

  • Bradley, A. J., & Dinan, T. G. (2010). A systematic review of hypothalamic–pituitary–adrenal axis function in schizophrenia: Implications for mortality. Journal of Psychopharmacology, 24(4 Supplement), 91–118.

    Article  PubMed  PubMed Central  Google Scholar 

  • British Medical Journal (BMJ). (2010). Long QT syndrome. British Medical Journal, 340:c366. doi: 10.1136/bmj.b4815.

    Google Scholar 

  • Campion, G., Francis, V., Preston, A., & Wallis, A. (2005). Health behaviour and motivation to change. Mental Health Nursing, 25, 12–15.

    Google Scholar 

  • Castillo, S. M., Fàbregas, E. M., Bergè, B. D., Goday, A. A., & Vallès, C. J. A. (2013). Psychosis, cardiovascular risk and associated mortality: Are we on the right track? Clinica Investigacion en Arteriosclerosis. doi:10.1016/j.arteri.2013.05.006.

    Google Scholar 

  • Castle, D., Baker, A. L., Richmond, R., Filia, S. L., Harris, D., & Pirola-Merlo, A. J. (2012). Varenicline plus healthy lifestyle intervention for smoking cessation in psychotic disorders. Annals of Clinical Psychiatry, 24(4), 285–291.

    PubMed  Google Scholar 

  • Celano, C. M., & Huffman, J. C. (2011). Depression and cardiac disease: A review. Cardiology Review, 19(3), 130–142.

    Article  Google Scholar 

  • Cooper, J., Mancuso, S. G., Borland, R., Slade, T., Galletly, C., & Castle, D. (2012). Tobacco smoking among people living with a psychotic illness: The second Australian survey of psychosis. Australian and New Zealand Journal of Psychiatry, 46, 851–863.

    Article  PubMed  Google Scholar 

  • Curtis, J., Newall, H., Shiers, D., & Samaras, K. (2012). Considering metformin in cardiometabolic protection in psychosis. Acta Psychiatrica Scandanavica, 126, 302–303.

    Article  Google Scholar 

  • Darke, S., Kaye, S., McKetin, R., & Duflou, J. (2008). Major physical and psychological harms of methamphetamine use. Drug and Alcohol Review, 27, 253–262.

    Article  PubMed  Google Scholar 

  • De Hert, M., Schreurs, V., Sweers, K., Van Eyck, D., Hanssens, L., Sinko, S., Wampers M.,… van Winkel, R. (2008). Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophrenia Research, 101, 295–303.

    Google Scholar 

  • De Hert, M., Cohen, D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer, J. W.,… Correll, C. U. (2011). Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry, 10(2), 138–151.

    Google Scholar 

  • Edwards, K. L., Chastain, L. M., Snodgrass, L., Martin, A., Busti, A. J. (2011) Effects of combined use of antiretroviral Agents and atypical antipsychotics on lipid parameters. Journal of Antivirals & Antiretrovirals, 3, 034–039.

    Google Scholar 

  • Fagiolini, A., & Goracci, A. (2009). The effects of undertreated chronic medical illnesses in patients with severe mental disorders. Journal of Clinical Psychiatry, 70(Supplement 3), 22–29.

    Article  PubMed  Google Scholar 

  • Friedman, J. I., Wallenstein, S., Moshier, E., Parrella, M., White, L., Bowler, S., Gottlieb, S.,… Davis, K. L. (2010). The effects of hypertension and body mass index on cognition in schizophrenia. American Journal of Psychiatry, 167(10), 1232–1239.

    Google Scholar 

  • Fusar-Poli, P., De Marco, L., Cavallin, F., Bertorello, A., Nicolasi, M., & Politi, P. (2009). Lifestyles and cardiovascular risk in individuals with functional psychoses. Perspectives in Psychiatric Care, 45(2), 87–99.

    Article  PubMed  Google Scholar 

  • Galletly, C. A., Foley, D. L., Waterreus, A., Watts, G. F., Castle, D. J., McGrath, J. J., Mackinnon, A., & Morgan, V. A. (2010). Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry, 46(8), 753–761.

    Article  Google Scholar 

  • Gierisch, J. M., Nieuwsma, J. A., Bradford, D. W., Wilder, C. M., Mann-Wrobel, M. C., McBroom, A. J., Wing, L.,… Williams, J. W. Jr. (2013). Interventions to improve cardiovascular risk factors in people with serious mental illness. Comparative effectiveness review No. 105. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 13-EHC063-EF. Rockville: Agency for Healthcare Research and Quality. April 2013. Retrieved from http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.

  • Giltay, E. J., Huijskes, R. V. H. P., Kho, K. H., Blansjaar, B. A., & Rosseel, P. M. J. (2006). Psychotic symptoms in patients undergoing coronary artery bypass grafting and heart valve operation. European Journal of Cardio-Thoracic Surgery, 30, 140–147.

    Article  PubMed  Google Scholar 

  • Green, A. I., Drake, R. E., Brunette, M. F., & Noordsy, D. L. (2007). Schizophrenia and co-occurring substance use disorder. American Journal of Psychiatry, 164, 402–408.

    Article  PubMed  Google Scholar 

  • Grundy, S. C., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin B. A., Gordon, D. J., … Costa, F. (2005). AHA/NHLBI scientific statement diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112, 2735–2752.

    Google Scholar 

  • Gupta, A., Bastiampillai, T., Adams, M., Nelson, A., & Nance, M. (2012). Varenicline induced psychosis in schizophrenia. Australian and New Zealand Journal of Psychiatry, 46(10), 1009.

    Article  PubMed  Google Scholar 

  • Haddad, P. M., & Anderson, I. M. (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62(11), 1649–1671.

    Article  PubMed  Google Scholar 

  • Harangozo, J., Reneses, B., Brohan, E., Sebes, J., Csukly, G., Lopez-Ibor, J., Sartorius, N.,… Thornicroft G. (2013). Stigma and discrimination against people with schizophrenia related to medical services. International Journal of Social Psychiatry. doi: 10.1177/0020764013490263.

    Google Scholar 

  • Hatta, K., Takahashi, T., Nakamura, H., & Yonezawa, Y. (2000). Prolonged QT interval in acute psychotic patients. Psychiatry Research, 94(3), 279–285.

    Article  PubMed  Google Scholar 

  • Henderson, D. C., Nguyen, D. D., Copeland, P. M., Hayden, D. L., Borba, C. P., Louie, P. M., Freundereich, O.,… Goff, D. C. (2005). Clozapine, diabetes, hyperlipidemia, cardiovascular risks and mortality. Results of a 10-year naturalistic study. Journal of Clinical Psychiatry, 66(9), 1116–1121.

    Google Scholar 

  • Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150, 1115–1121.

    Article  PubMed  Google Scholar 

  • John, A. P., Koloth, R., Dragovic, M., & Lim, S. C. (2009). Prevalence of metabolic syndrome among Australians with severe mental illness. Medical Journal of Australia, 190, 176–179.

    PubMed  Google Scholar 

  • Johnsen, E., Gjestad, R., Kroken, R. A., Mellesdal, L., Loberg, E.-M., & Jorgensen, H. A. (2011). Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study. Nord Journal of Psychiatry, 65, 192–202.

    Article  Google Scholar 

  • Koolhaas, J. M., Bartolomucci, A., Buwalda, B., de Boer, S. F., Flügge, G., Korte, S. M., Meerlo, P.,… Fuchs, E. (2011). Stress revisited: A critical evaluation of the stress concept. Neuroscience & Biobehavioral Reviews, 35(5), 1291–1301.

    Google Scholar 

  • Lahti, M., Tihonen, J., Wildgust, H., Beary, M., Hodgson, R., Kajantie, E., … Eriksson, J. (2012). Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychological Medicine, 42(11), 2275–2285.

    Google Scholar 

  • Lambert, T. (2011). Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Australian Prescriber, 34, 97–99.

    Article  Google Scholar 

  • Lancet. (2011). No mental health without physical health. Lancet, 377(9766), 611.

    Article  Google Scholar 

  • Layland, J. L., Liew, D., & Prior, D. L. (2009). Clozapine-induced cardiotoxicity: A clinical update. Medical Journal of Australia, 190, 190–192.

    PubMed  Google Scholar 

  • Leonard, B., Schwarz, M., & Myint, I. M. (2012). The metabolic syndrome in schizophrenia: Is inflammation a contributing cause? Journal of Psychopharmacology, 26(5 Supplement), 33–41.

    Article  PubMed  Google Scholar 

  • Mackin, P. (2008). Cardiac side effects of psychiatric drugs. Human Psychopharmacology: Clinical and Experimental, 23, 3–14.

    Article  Google Scholar 

  • McBride, O., Teesson, M., Slade, T., Hasin, D., Degenhardt, L., & Baillie, A. (2009). Further evidence of differences in substance use and dependence between Australia and the United States. Drug and Alcohol Dependence, 100, 258–264.

    Article  PubMed  Google Scholar 

  • McCreadie, R. (2003). Diet, smoking and cardiovascular risk in people with schizophrenia. British Journal of Psychiatry, 183, 534–549.

    Article  PubMed  Google Scholar 

  • McDermott, S., Moran, R., Platt, T., Isaac, T., Wood, H., & Dasari, S. (2005). Heart disease, schizophrenia, and affective psychoses: Epidemiology of risk in primary care. Community Mental Health Journal, 41(6), 747–755.

    Article  PubMed  Google Scholar 

  • McNamee, L., Mead, G., MacGillivray, S., & Lawrie, S. M. (2013). Schizophrenia, poor physical health and physical activity: Evidence-based interventions are required to reduce major health inequalities. British Journal of Psychiatry, 203, 239–241.

    Article  PubMed  Google Scholar 

  • Meltzer, H. (2012). Clozapine: Balancing safety with superior antipsychotic efficacy. Clinical Schizophrenia & Related Psychoses, 6(3), 134–144.

    Article  Google Scholar 

  • Morgan, V. A., Waterreus, A., Jablensky, A., Mackinnon, A., McGrath, J. J., Carr, V., Bush, R.,… Saw, S. (2012). People living with psychotic illness in 2010: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry, 46(8), 735–752.

    Google Scholar 

  • Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. American Family Physician, 81(5), 617–622.

    PubMed  Google Scholar 

  • Murphy, K. C. (2002). Schizophrenia and velo-cardio-facial syndrome. Lancet, 359(9304), 426–430.

    Article  PubMed  Google Scholar 

  • Ohlsen, R. (2011). Schizophrenia: A major risk factor for cardiovascular disease. British Journal of Cardiac Nursing, 6(5), 2–6.

    Article  Google Scholar 

  • Ojalaa, K., Niskanenb, L., Tiihonena, J., Paavolaa, P., Putkonena, A., & Repo-Tiihonen, E. (2008). Characterization of metabolic syndrome among forensic psychiatric inpatients. Journal of Forensic Psychiatry & Psychology, 19(1), 33–51.

    Article  Google Scholar 

  • Organ, B., Nicholson, E., & Castle, D. (2010). Implementing a physical health strategy in a mental health service. Australasian Psychiatry, 18(5), 456–459.

    Article  PubMed  Google Scholar 

  • Pollitt, R. A., Daniel, M., Kaufman, J. S., Lynch, J. W., Salonen, J. T., & Kaplan, G. A. (2005). Mediation and modification of the association between hopelessness, hostility, and progression of carotid atherosclerosis. Journal of Behavioral Medicine, 28, 53–64.

    Article  PubMed  Google Scholar 

  • Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine, 360, 225–235.

    Article  PubMed  PubMed Central  Google Scholar 

  • Roberts, L., Roalfe, A., Wilson, S., & Lester, H. (2007). Physical health care of patients with schizophrenia in primary care: A comparative study. Family Practice, 24, 34–40.

    Article  PubMed  Google Scholar 

  • Rosenberg, S. D., Goodman, L. A., & Osher, F. C. (2001). Prevalence of HIV, hepatitis B & C in people with severe mental illness. American Journal of Public Health, 91, 31–37.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ruest, C. (2011). Common adverse effects of antiretroviral therapy for HIV disease. American Family Physician, 83(12), 1443–1451.

    Google Scholar 

  • Siris, S. G. (2000). Depression in schizophrenia: Perspective in the era of “atypical” antipsychotic agents. American Journal of Psychiatry, 157, 1379–1389.

    Article  PubMed  Google Scholar 

  • Smith, D. J., Langan, J., McLean, G., Guthrie, B., Mercer, S. W. (2013). Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: Cross-sectional study. British Medical Journal open, 3(4). pii: e002808. doi:10.1136/bmjopen-2013-002808,

    Google Scholar 

  • Tang, A., O’Sullivan, A. J., Diamond, T., Gerard, A., & Campbell, P. (2013). Psychiatric symptoms as a clinical presentation of Cushing’s syndrome. Annals of General Psychiatry, 12, 23.

    Article  PubMed  PubMed Central  Google Scholar 

  • Taylor, D. An editorial comment to Curtis J, Newall H, Shiers D, Samaras K. (2012). Considering metformin in cardiometabolic protection in psychosis. Acta Psychiatrica Scandinavica, 126(4), 233–234.

    Google Scholar 

  • van Os, J. (2009). A salience dysregulation syndrome. British Journal Psychiatry, 194(2), 101–103.

    Article  Google Scholar 

  • Verhaeghe, N., De Maeseneer, J., Maes, L., Van Heeringen, C., & Annemans, L. (2011). Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: A systematic review. International Journal of Behavioral Nutrition and Physical Activity, 8, 28.

    Article  PubMed  PubMed Central  Google Scholar 

  • Vinas, C. L., Fernandez, S.-M. M. I., Martin, L. L. M., & Grupo, P. L. (2013). Effectiveness of a joint project between primary care and mental health to improve the recording of cardiovascular risk factors in patients with psychosis. Atencion Primaria, 45(6), 307–314.

    Article  Google Scholar 

  • Viron, M., Baggett, T., Hill, M., & Freudenreich, O. (2012). Schizophrenia for primary care providers: How to contribute to the care of a vulnerable patient population. American Journal of Medicine, 125(3), 223–230.

    Article  PubMed  Google Scholar 

  • Volkow, D. (2009). Substance use disorders in schizophrenia—clinical implications of comorbidity. Schizophrenia Bulletin, 35(3), 469–472.

    Article  PubMed  PubMed Central  Google Scholar 

  • Werner, S., Malaspina, D., & Rabinowitz, J. (2007). Socioeconomic status at birth is associated with risk of schizophrenia: Population-based multilevel study. Schizophrenia Bulletin, 33(6), 1373–1378.

    Article  PubMed  PubMed Central  Google Scholar 

  • World Health Organisation. (1994). International statistical classification of diseases and health related problems. Geneva: World Health Organization.

    Google Scholar 

  • Yap, S., Boers, G. H. J., Wilcken, B., Wilcken, D. E. L., Brenton, D. P., Lee, P. J., Walter, J. H.,… Naughten, E. R. (2001). Vascular outcome in patients with homocystinuria due to cystathionine β-synthase deficiency treated chronically: A multicenter observational study. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 2080–2085.

    Google Scholar 

  • Younossi, Z. M., Stepanova, M., Nader, F., Younossi, Z., & Elsheikh, E. (2013). Associations of chronic hepatitis C with metabolic and cardiac outcomes. Alimentary Pharmacology and Therapeutics, 37(6), 647–652.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St Vincent’s Hospital, 3065, Melbourne, VIC, Australia

    Peter Bosanac & David Castle

  2. University of Melbourne, Melbourne, VIC, Australia

    Peter Bosanac & David Castle

Authors
  1. Peter Bosanac
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Castle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Bosanac .

Editor information

Editors and Affiliations

  1. Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia

    Marlies E. Alvarenga

  2. ANU Medical School, Australia National University, Canberra, Aust Capital Terr, Australia

    Don Byrne

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Her Majesty the Queen in Right of Australia

About this entry

Cite this entry

Bosanac, P., Castle, D. (2016). Psychoses and Cardiovascular Disease: The Heart and Mind of the Matter. In: Alvarenga, M., Byrne, D. (eds) Handbook of Psychocardiology. Springer, Singapore. https://doi.org/10.1007/978-981-287-206-7_15

Download citation

Publish with us

Policies and ethics

Search

Navigation